Table 5.
Summary of some baseline characteristics of Studies 1 and 2, that is, frequencies (number of dogs and percentages) or medians (interquartile range)
| Variable | Study 1 | Study 2 | ||||
|---|---|---|---|---|---|---|
| Treatment group | Global (n = 151) | Treatment group | Global (n = 215) | |||
| Torasemide (n = 75) | Furosemide (n = 76) | Torasemide (n = 105) | Furosemide (n = 110) | |||
| Male, n (%) | 54 (72) | 45 (59) | 99 (66) | 65 (62) | 64 (58) | 129 (60) |
| Female, n (%) | 21 (28) | 31 (41) | 52 (34) | 40 (38) | 46 (42) | 86 (40) |
| Agea (years) | 12.00 [10.2–14.0] | 11.0 [10.0–13.6] | 12.0 [10.1–14.0] | 12.00 [10.2–13.8] | 12.7 [10.6–14.2] | 12.2 [10.3–14.0] |
| Body weighta (kg) | 7.8 [6.0–11.1] | 7.9 [5.6–10.9] | 7.9 [5.7–11.1] | 7.2 [4.6–10.9] | 8.1 [5.7–12.2] | 7.8 [5.3–11.8] |
| Composite clinical scorea | 3 [2–4] | 3 [2–4] | 3 [2–4] | 4 [3–5] | 4 [2–4] | 4 [2–5] |
| NYHA class (II/III/IV), n (%) | 37 (50)/31 (41)/7 (9) | 35 (46)/33 (43)/8 (11) | 72 (48)/64 (42)/15 (10) | 46 (44)/43 (41)/16 (15) | 42 (38)/57 (52)/11 (10) | 88 (41)/100 (46)/27 (13) |
| IRIS class (1/2/3/4), n (%) | 63 (84)/10 (13)/2 (3)/0 (0) | 69 (91)/4 (5)/2 (3)/1 (1) | 132 (87)/14 (9)/4 (3)/1 (1) | 91 (87)/10 (9)/3 (3)/1 (1) | 88 (80)/17 (15)/5 (5)/0 (0) | 179 (83)/27 (13)/8 (4)/1 (0) |
| Diuretic dosea (mg/kg/d) | 0.24 [0.19–0.40] | 2.86 [2.06–5.07] | – | 0.24 [0.19–0.34] | 2.63 [1.89–4.55] | – |
a
Median [1st quartile – 3rd quartile]; NYHA, New York Heart Association; IRIS, International Renal Interest Society.